NCT04147312 (FFEJJICRF) is a NA clinical trial of Fufang E'Jiao Jiang in Cancer-related Fatigue, sponsored by Xiyuan Hospital of China Academy of Chinese Medical Sciences.

Who is sponsoring NCT04147312?

NCT04147312 is sponsored by Xiyuan Hospital of China Academy of Chinese Medical Sciences.

What drugs are being tested in NCT04147312?

Interventions in NCT04147312: Fufang E'Jiao Jiang, placebo containing low-dose fufang E'Jiao Jiang.

What condition does NCT04147312 study?

NCT04147312 studies Cancer-related Fatigue.

Is NCT04147312 still recruiting?

NCT04147312 is currently status unknown. Last updated 25 February 2020.

Last reviewed 2020-02-25 · How we verify

NCT04147312: FFEJJICRF

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Fufang E'Jiao Jiang Intervening Cancer-related Fatigue

Status unknown NA Last updated 25 February 2020

What this trial tests

NA trial testing Fufang E'Jiao Jiang in Cancer-related Fatigue in 600 participants. Status unknown.

Timeline

17 October 2019

Primary endpoint
31 May 2021

31 December 2021

Quick facts

Lead sponsor	Xiyuan Hospital of China Academy of Chinese Medical Sciences
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	supportive care
Enrollment	600
Start date	17 October 2019
Primary completion	31 May 2021
Estimated completion	31 December 2021
Sites	1 location across China

Drugs / interventions tested

Fufang E'Jiao Jiang — full drug profile →
placebo containing low-dose fufang E'Jiao Jiang — full drug profile →

Conditions studied

Cancer-related Fatigue — all drugs for Cancer-related Fatigue →

Sponsor

Xiyuan Hospital of China Academy of Chinese Medical Sciences

Who can join

Adults 18 to 75, any sex, with Cancer-related Fatigue. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

With the therapeutic tool of carcinoma increasing, life span extending, the solicitude for the patients'quality of life appear more important. Cancer-related fatigue (CRF) is one of the most prevalent and debilitating symptoms experienced by people with cancer. It can persist for months or years after cancer therapy is completed and has a negative impact on all areas of function. Meaningful evidence-based treatment options for CRF are extremely limited and finding safe, inexpensive, and effective interventions for managing this distressing symptom are urgently needed. Our previous clinical experience have shown that traditional Chinese medicine（TCM） had a great effect on improving CRF, Several studies proven that its'mechanism were related to the regulation of immune function and endocrine hormones. Fufang E'Jiao Jiang (FFEJJICRF) is a commonly-used Chinese patent medicine and successfully marketed in China for many years, which are effective in improvement for TCM symptoms of deficiency with qi and blood. This proposal will investigate the effects of FFEJJICRF on CRF among non-small cell lung cancer, colorectal cancer, and gastric cancer, so as to find a new way for curing it in clinical.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Exploring the Safety, Effectiveness, and Cost-Effectiveness of a Chinese Patent Medicine (Fufang E'jiao Syrup) for Alleviating Cancer-Related Fatigue: A Protocol for a Randomized, Double-Blinded, Placebo-Controlled, Multicenter Trial.
Song Z, Sun LY, Gu SS, Zhu XS, et al · · 2021 · cited 5× · PMID 33834863 · DOI 10.1177/15347354211002919

Verify or expand the search:

Other recruiting trials for Cancer-related Fatigue

Currently open trials in the same condition.

NCT05891431 — Engagement and Acceptability of the Untire mHealth App · NA · active not recruiting

Other Xiyuan Hospital of China Academy of Chinese Medical Sciences trials

Trials by the same sponsor.

NCT07518420 — Clinical Efficacy Evaluation of Chaizhi Hewei Decoction in the Treatment of Non-Erosive Reflux Disease With Liver-Stomac · NA · not yet recruiting
NCT06845254 — Clinical Study on the Intervention of Xuesaitong Soft Capsules in Post-Intervention Patients with Acute Coronary Syndrom · Phase 3 · not yet recruiting
NCT06618495 — Clinical Study and Molecular Mechanism of Xuesaitong Soft Capsule in the Treatment of Acute Coronary Syndrome · Phase 1, PHASE2 · completed
NCT06311890 — Study to Evaluate the Efficacy, Safety and Tolerability of Photodynamic Therapy(PDT) With Chlorin-e6 in Treating Moderat · Phase 2 · recruiting
NCT05638672 — COVID-19 Huashi Baidu Formula Clinical Study · NA · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04147312 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Xiyuan Hospital of China Academy of Chinese Medical Sciences
Last refreshed: 25 February 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04147312.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing